Brief: Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
10/11/2023 13:52
Nov 10 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS ANNOUNCES EUROPEAN PATENT OFFICE
DECISION
TO GRANT FOR PATENT APPLICATION COVERING INTRANASAL BETAHISTINE
* ALTAMIRA THERAPEUTICS LTD - PATENT APPLICATION IS EXPECTED
TO
REMAIN VALID UNTIL FEBRUARY 2038
Source text for Eikon: ID:nGNX8PvV9k
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering